Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.

Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W; RATE-RA Study Group.

BMC Musculoskelet Disord. 2014 May 24;15:177. doi: 10.1186/1471-2474-15-177.

2.
3.

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.

Mishra R, Singh V, Pritchard CH.

Rheumatol Int. 2011 Apr;31(4):481-4. doi: 10.1007/s00296-009-1307-7. Epub 2009 Dec 20.

4.

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE.

J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23.

PMID:
20032102
5.

Patellar tendon rupture in systemic lupus erythematosus.

Pritchard CH, Berney S.

J Rheumatol. 1989 Jun;16(6):786-8.

PMID:
2778760

Supplemental Content

Loading ...
Support Center